Clinical Trials Logo

Melanoma (Skin) clinical trials

View clinical trials related to Melanoma (Skin).

Filter by:

NCT ID: NCT00962845 Completed - Melanoma (Skin) Clinical Trials

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Start date: September 2010
Phase: Early Phase 1
Study type: Interventional

RATIONALE: Studying samples of blood, tumor tissue, and skin in the laboratory from patients with melanoma receiving hydroxychloroquine may help doctors understand the effect of hydroxychloroquine on biomarkers. PURPOSE: This early phase I trial is studying hydroxychloroquine in patients with stage III or stage IV melanoma that can be removed by surgery.

NCT ID: NCT00937781 Completed - Melanoma (Skin) Clinical Trials

Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690

Start date: February 8, 2011
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tumor tissue samples from patients with melanoma treated on clinical trial EST-1690.

NCT ID: NCT00898183 Completed - Melanoma (Skin) Clinical Trials

S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma

Start date: November 1996
Phase:
Study type: Observational

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is assessing genes and immune response in tumor samples from patients with locally advanced or metastatic melanoma.

NCT ID: NCT00897546 Completed - Melanoma (Skin) Clinical Trials

Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma

Start date: June 1, 2007
Phase: N/A
Study type: Observational

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer, and may help doctors learn how well patients will respond to treatment. PURPOSE: This laboratory study is looking at biomarkers to predict the response to interferon therapy in patients with melanoma.

NCT ID: NCT00897520 Completed - Melanoma (Skin) Clinical Trials

Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy

Start date: January 14, 2008
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer and predict how patients will respond to treatment. PURPOSE: This research study is looking at biomarkers in patients with high-risk melanoma receiving high-dose interferon therapy.

NCT ID: NCT00866840 Completed - Melanoma (Skin) Clinical Trials

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Start date: April 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This phase II trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.

NCT ID: NCT00798629 Completed - Melanoma (Skin) Clinical Trials

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Start date: November 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with metastatic melanoma.

NCT ID: NCT00755976 Completed - Melanoma (Skin) Clinical Trials

Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

Start date: August 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sulindac together with epirubicin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sulindac together with epirubicin works in treating patients with metastatic malignant melanoma.

NCT ID: NCT00705640 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Advanced Melanoma

Mel48
Start date: May 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.

NCT ID: NCT00700882 Completed - Melanoma (Skin) Clinical Trials

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Start date: July 2, 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma or acral melanoma.